Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Sih Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,828,737

148 payments

Through program year 2023, Sih Research LLC is reported as receiving $1,828,737 in research payments, across 148 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $10,964 3
2022 Research $138,717 5
2021 Research $24,735 9
2020 Research $494,414 43
2019 Research $1,159,907 88

Breakdown

Who paid Research payments · program years 2019–2023
  1. AbbVie, Inc. $1,169,647 78 payments
  2. Allergan Inc. $337,927 35 payments
  3. AstraZeneca Pharmaceuticals LP $169,847 11 payments
  4. Shire North American Group Inc $89,931 15 payments
  5. Eli Lilly and Company $30,049 6 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $18,686 2 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $12,650 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. M15-991 $486,754 27 payments
  2. M16-006 $465,984 29 payments
  3. M16-000 $216,909 22 payments
  4. A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $86,636 6 payments
  5. A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $85,579 9 payments
  6. A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $83,952 2 payments
  7. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $59,826 5 payments
  8. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $56,164 5 payments
  9. This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy $49,433 5 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $44,087 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record